Clinical Trial Update: A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating MK-7264-012 in participants with refractory chronic cough has completed; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough

Drugs mentioned

• MK-7264 (MK-7264)

Snippet

Sponsor: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Refractory Chronic Cough | Phase 2 | Status: COMPLETED | Results posted: 2018-02-14